---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-204006"
form_type: "8-K"
ticker: "RNTX"
cik: "0001420565"
company_name: "Rein Therapeutics, Inc."
filed_at: "2026-05-04T23:59:59+00:00"
generated_at: "2026-05-14T23:51:44.826001+00:00"
event_type: "other"
sentiment: "neutral"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Rein Therapeutics prices $50M public offering of 50M shares at $1.00/share

## Summary
- Gross proceeds $50M from 50M shares at $1.00; net proceeds ~$46.1M after discounts and expenses.
- Underwriter granted 45-day option for up to 7.5M additional shares; warrants for 3% of sold shares at $1.50.
- Bios entities defer conversion of 12,232 Series X preferred shares and lock-up through April 2029; receive 3M warrants at $1.00.
- Proceeds to fully fund Phase 2 trial of LTI-03 in IPF; cash runway extended into 2028.
- Konik Capital Partners (T.R. Winston) acts as sole book-running manager.

## SEC filing metadata
- accession: 0001193125-26-204006
- form_type: 8-K
- ticker: RNTX
- cik: 0001420565
- company_name: Rein Therapeutics, Inc.
- filed_at: 2026-05-04T23:59:59+00:00
- event_type: other
- sentiment: neutral
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 1.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1420565/000119312526204006/0001193125-26-204006-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1420565/000119312526204006/d168655d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-204006
- JSON: https://secwatch.observer/filing/0001193125-26-204006.json
- Plain text: https://secwatch.observer/filing/0001193125-26-204006.txt

## Source-grounded claims
- claim_id: 075a3b170dc8b75c1501f3553679aba8e86c1b42
  claim: Rein Therapeutics, Inc. entered into Underwriting Agreement with Konik Capital Partners, LLC valued at $1.00 per share, before underwriting discounts and commissions (effective 2026-04-30).
  evidence_excerpt: On April 30, 2026, Rein Therapeutics, Inc., a Delaware corporation (the “Company”), entered into an Underwriting Agreement (the “Underwriting Agreement”) with Konik Capital Partners, LLC, a division of T.R. Winston & Company, LLC, acting as sole book-running manager, relating to the issuance and sale of 50,000,000 shares of the Company’s common stock, par value $0.001 per share (the “Offering”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1420565/000119312526204006/0001193125-26-204006-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.